fda glp-1 news november 2025 GLP-1s in 2026: What Brokers Need to Know 2026 is the year of

In the past six months, the agency stated it has sent thousands of letters to pharmaceutical and telehealth companies directing them to remove misleading advertisements, more than had been sent over the entire preceding decade

No state-licensing verification, prescribing without evaluation, no follow-up, vague pricing or sourcing, and exaggerated promises

Your provider titrates your dose based on your clinical response

Ozempic was first approved by the FDA in 2017 as a diabetes treatment and its use, alongside other GLP-1 agonist medications, has been in the spotlight in recent years

Ganpath recommends keeping a symptom diary to help you track when fatigue occurs, its severity, and any accompanying symptoms